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Background: Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome that is commonly
associated with a germline mutation in the tumor suppressor gene p53. Loss of p53 results in increased expression
of CD44, a cancer stem cell (CSC) marker, which is involved in the scavenging of reactive oxygen species (ROS).
Here, we report a change in the expression of a CD44 variant isoform (CD44v8-10) in an 8-year-old female LFS
patient with osteosarcoma and atypical liver cancer after chemotherapy.
Case presentation: The patient visited a clinic with a chief complaint of chronic pain in a bruise on her right knee.
Magnetic resonance imaging (MRI) raised the possibility of a bone malignancy. Biochemical testing also revealed
significantly elevated levels of AFP, which strongly suggested the existence of a primary malignancy in the liver.
MRI imaging showed the simultaneous development of osteosarcoma and liver cancer, both of which were
confirmed upon biopsy. Combined therapy with surgical resection after chemotherapy was successful in this
patient. Regardless of the absence of a familial history of hereditary cancer, a germline mutation in p53 was
identified (a missense mutation defined as c.722 C>T, p.Ser241Phe). To better understand the cancer progression
and response to treatment, immunohistochemical (IHC) analysis of biopsy specimens obtained before and after
chemotherapy was performed using a specific antibody against CD44v8-10.
Conclusion: This case demonstrates the ectopic up-regulation of CD44v8-10 in a biopsy sample obtained after
cytotoxic chemotherapy, which confers high levels of oxidative stress on cancer cells. Because the alternative
splicing of CD44 is tightly regulated epigenetically, it is possible that micro-environmental stress resulting from
chemotherapy caused the ectopic induction of CD44v8-10 in vivo.
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Li-Fraumeni syndrome (LFS) is a familial cancer predis-
position syndrome, which is inherited in an autosomal
dominant manner. This syndrome is most frequently
associated with soft tissue sarcoma, osteosarcoma, pre-
menopausal breast cancer, brain cancer, and adreno-
cortical carcinoma, but it can also result in other types* Correspondence: yfuchimoto@z5.keio.jp
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reproduction in any medium, provided the orof tumors. LFS is classified into two major subgroups:
classic LFS and Li-Fraumeni-like (LFL) syndrome, which
shares some, but not all, of the features of LFS [1-3].
Juvenile development of simultaneous and multiple
cancers raises the possibility of LFS.
Sequence analysis of the entire p53 coding region
(exons 2–11) detects about 95% of p53 mutations, most
of which are missense mutations. A functional assay
may be useful for determining the clinical significance
of novel missense mutations [4]. It has been indicated
that approximately 70% of LFS patients and 8–22% ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mutations [5]. Comprehensive analyses of genotype-
phenotype correlations have led to a better understand-
ing of tumors that are associated with germline p53
mutations [6].
CD44 is an adhesion molecule for extracellular matrix
components such as hyaluronic acid and osteopontin
[7], and plays an important role not only in wound
healing and cell migration, but also in tumor invasion
and metastasis. CD44 has numerous isoforms generated
through alternative mRNA splicing. For instance, CD44v6
interacts with c-Met, the receptor of hepatocyte growth
factor (HGF), thereby increasing the survival and prolif-
erative ability of tumor cells That is one of the reasons
why the expression of the CD44 splice variant CD44v6 is
correlated with the metastasis of colon cancer to the liver
and a poor clinical prognosis [8]. CD44 has been recently
identified as one of the cellular surface markers associated
with cancer stem cells (CSCs) in several types of tumors.
Notably, CD44 variants (CD44v) are exclusively expressed
in epithelial-type cells, whereas the CD44 standard iso-
form (CD44s) is expressed in both epithelial and mesen-
chymal cells [9].
Loss-of-functional mutations in the p53 gene promote
tumor development. CD44 expression is generally sup-
pressed by p53 binding to the CD44 promoter, so that
increased expression of CD44 is detected in tumor cells
with mutant p53 [10].
CSCs are defined as the small population of cancer
cells with multi-lineage differentiation potential. These
self-sustaining cells have the exclusive ability to self-
renew and maintain the tumor tissue [11]. CSCs often
fail to respond to chemotherapy, thereby causing distant
metastasis and latent relapse. For this reason, we focusedLiver tumor
Osteosarcoma
Before chemotherapy
Figure 1 Reduced tumor masses in the liver and bone after chemoth
both the liver tumor and the osteosarcoma were significantly reduced by ton the change in tumor expression of CD44 as a result
of chemotherapy. Minimal residual disease (MRD) after
chemotherapy is expected to be enriched in CSCs com-
pared with the pre-chemotherapy tumor specimen.
Alternative splicing is mainly responsible for the diver-
sity of CD44 isoforms. Among these variants, CD44v8-
10 enhances reduced glutathione (GSH) synthesis by
stabilizing the xCT transport system for cysteine, the
precursor of GSH. Hence, CSCs acquire an enhanced
reactive oxygen species (ROS) defense system [12]. Cyto-
toxic drugs such as Adriamycin induce apoptosis by caus-
ing oxidative stress, which damages DNA. To better
understand the influence of oxidative stress on the tumor
microenvironment, changes in the expression of CD44v8-
10 were evaluated in response to chemotherapy. We
hypothesized that oxidative stress due to the administra-
tion of cytotoxic chemotherapy would affect the expression
of CD44v8-10 in p53-mutated cancer cells in this patient.
Case presentation
An 8-year-old female slipped on the stairs and had a
bruise on her right knee. However, since the pain per-
sisted, the patient visited a nearby orthopedic clinic.
Magnetic resonance imaging (MRI) revealed the possi-
bility of a bone malignancy (Figure 1). The patient was
then admitted to the hospital for further examination.
Biochemical testing revealed significantly elevated levels
of both serum AFP (AFP: 79016 ng/ml, L3: 3555 ng/ml
(4.5%), PIVKA-II: 128 IU/l), which suggested possible
malignancy of the liver. A serum AFP level as high as
79,000 ng/ml was also indicative of a liver tumor. Anti-
bodies against hepatitis virus B and C were not detected.
The development of hepatoblastoma was atypical in
terms of the age of onset, given that hepatoblastomasAfter chemotherapy
erapy. Magnetic resonance imaging (MRI) revealed that the sizes of
he combination chemotherapy.
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logical diagnosis was transitional liver cell tumor
(TLCT). A subset of liver cell tumors in older children
and adolescents may develop as an intermediate between
blastomatous tumors and adult-type tumors. This type
of tumor, referred to as TLCT, is highly dependent on
Wnt signaling than other categories of liver tumors [13].
MRI imaging showed the simultaneous development of
osteosarcoma and liver cancer (Figure 1), both of which
were confirmed by biopsy. After two courses of standard
neoadjuvant chemotherapy for hepatoblastoma (a com-
bination of cisplatin (CDDP) and tetrahydropyranyl-
adriamycin (THP-ADR)), the residual liver tumor was
removed completely by surgical extended lobectomy.
After treatment with the standard neoadjuvant chemo-
therapy protocol for osteosarcoma (a combination of
CDDP, ifosfamide (IFO), and methotrexate (MTX)), the
diminished osteosarcoma was totally resected and an
artificial joint was placed. The levels of transitional
serum biomarkers for the liver tumor and osteosarcoma
are shown (Figure 2), in which the blue arrows indicate
repeated neoadjuvant chemotherapy. To date, there has
been no sign of relapse or latent metastasis for about
two years after last surgery. Combined therapy with sur-
gical resection after chemotherapy was, therefore, success-
ful in this patient. Given that we found the simultaneous
development of a liver tumor and osteosarcoma, we per-
formed genetic testing to evaluate the patient’s suscepti-
bility to malignancy. Despite the absence of a familial
history of hereditary cancer, a germline mutation in p53
(c.722 C>T, p.Ser241Phe) was identified. Notably, theFigure 2 Transitional serum biomarkers for liver cancer and osteosarc
resulted in a significant decrease in serum tumor markers for liver cancer a
tumor, whereas LDH and ALP are serum markers for the osteosarcoma.frequency of de novo mutations in LFS is between 7% and
20% [14]; it is, therefore, conceivable that the p53 muta-
tion occurred de novo during embryonic development.
Immunohistochemical (IHC) analysis of the patient’s
tumors prior to and following chemotherapy was per-
formed using an antibody against the human CD44
variant isoform. CD44v8-10 was not expressed in both
the liver tumor and the osteosarcoma before chemo-
therapy, but was ectopically expressed after chemother-
apy (Figure 3).
Discussion and conclusion
CD44 exists in as many as 16 different isoforms,
which are generated through alternative mRNA splicing.
CD44v8-10 is generated by epithelial splicing regulatory
protein 1 (ESRP1), an RNA-binding protein [15].
Whereas the standard CD44 isoform (CD44s), which
contains exons 1–5 and 16–20, is expressed predomin-
antly in hematopoietic cells and normal epithelial cell
subsets, CD44 variant isoforms with insertions in the
membrane-proximal extracellular region are abundant in
epithelial-type cancers, including liver tumors. Recently,
CD44v8-10 was reported to have a novel function; it
inhibits oxidative stress in tumor cells by promoting the
GSH synthesis [12]. However, exactly transcriptional fac-
tors or epigenetic mechanisms controlling the induction
of ESRP1, the master regulator of CD44v8-10, remain
unclear [9]. We have already performed IHC using the
specific antibody against human ESRP1 and ESRP2. Un-
fortunately, there was no antibody which was suitable
for IHC due to reactions to the non-specific antigens, sooma. Combined therapy with surgical resection after chemotherapy
nd osteosarcoma. AFP and L-3 are serum markers for the hepatic
(a) (b) 
(c) (d) 
Figure 3 CD44v8-10 IHC of both tumors before and after chemotherapy. Immunohistochemical analysis of a transitional liver cell tumor
(TLCT) prior to chemotherapy (a), a post-chemotherapy TLCT tissue (b), an osteosarcoma biopsy tissue sample obtained prior to chemotherapy
(c), and a post-chemotherapy osteosarcoma tissue (d) stained with an antibody against CD44v8-10 (Inset: higher magnification; scale bar: 10 μm).
(Inset: higher magnification; scale bar: 10 μm).
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ESRP2 exclusively in the nucleus (data not shown).
Osteosarcoma originates from mesenchymal tissue,
not epithelial tissue, meaning that the CD44 variant iso-
forms expressed in osteosarcoma may have a completely
different function from those expressed in liver cancer.
Whereas the function of CD44v8-10 in osteosarcoma is
unknown, the only v6 expression is negatively correlated
with 5-year metastasis-free survival. Therefore, overex-
pression of the variant isoform, CD44v6, is considered a
poor prognostic marker in patients with osteosarcoma
[15]. However, no specific data has been reported
regarding the biological significance of CD44v8-10 in
osteosarcoma. The cytotoxic drugs CDDP and THP-
ADR increase the ROS level in cancer cells, thereby in-
ducing DNA damage and apoptosis. It is possible that
CD44v8-10 is induced following chemotherapy in osteo-
sarcoma to counteract this oxidative stress.
Considering the lack of familial history of malignancy
in this case, it is supposed that the de novo p53 germline
mutation occurred during early development. The p53
protein suppresses expression of CD44 by binding to the
promoter region of CD44 [10], and CD44v8-10 was not
expressed in both tumors before chemotherapy. The ab-
sence of p53 likely enabled the upregulation of CD44v8-
10 in response to chemotherapy. However, this findingdoes not rule out the possibility that other CD44 iso-
forms were fully expressed prior to chemotherapy.
Although cancer cells may acquire resistance to oxida-
tive damage by upregulating CD44v8-10, there has been
no sign of relapse or metastasis so far in this patient.
The fact that CD44v8-10 expression was not correlated
with increased malignant potential in this case seems to
be contradictory to our previous research [12]; however,
the effect of CD44v8-10 expression may depend on the
origin of the tumor. It is possible that CD44v8-10 may
function differently in hepatic tumors and osteosar-
comas with p53 mutations than in gastric and colorectal
cancers.
Potential mechanisms for the ectopic induction of
CD44v8-10 expression in osteosarcoma are shown
(Figure 4):
a) Cancer cells expressing CD44v8-10 may have existed
in the original tumor, but were too rare to be
detected by IHC. These cells survived even under
conditions of oxidative stress caused by cytotoxic
chemotherapy.
b) Cancer cells expressing CD44v8-10 did not exist
originally, but the oxidative stress caused by
chemotherapy induced the expression of CD44v8-10
in the tumor.
(a)
: Cancer cell with CD44v8-10
: Cancer cell without CD44v8-10
Oxidative stress caused by 
chemotherapy
Oxidative stress caused by 
chemotherapy
(b)
Figure 4 Two hypothetical models for the induction of
CD44v8-10 after chemotherapy. Cancer cells expressing
CD44v8-10 are present in the original tumor and clonally expand in
response to anti-cancer drugs (a). Cancer cells with CD44v8-10 are
absent from the original tumor, but oxidative stress caused by
chemotherapy induces the ectopic expression of CD44v8-10 (b).
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further investigation into how the alternative splicing
machinery for CD44 is affected by chemotherapy. There
has been no sign of relapse or metastasis so far in this
patient, but it will be crucial to gather additional data
regarding CSC molecular dynamics during the course of
chemotherapy. Therefore, a larger number of cancer
cases need to be analyzed, and longer-term follow-up
studies must be conducted, to confirm the results of this
study.
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